个人中心 - 老虎社区

Lavon

IP属地：广东

帖子 · 2帖子 · 2
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- LavonLavon
  ·04-16
  这篇文章不错，转发给大家看看
  映恩生物正式挂牌港交所
  观点网讯：4月15日，映恩生物Duality Biotherapeutics, Inc.在香港联合交易所主板成功挂牌上市。映恩生物此次招股公开发售部分获115.14倍认购，国际发售部分获13.52倍认购。映恩生物此次IPO引入15名基石投资者，合共认购534.18万股发售股份，包括BioNTech、LAV Star等。截至最后实际可行日期，映恩生物在17个国家的230多个临床试验中心拥有七项全球多区域临床试验，已有2,000多名患者入组。
  映恩生物正式挂牌港交所
  272 评论
  1
  分享
  举报
- LavonLavon
  ·2024-10-04
  Replying to @AliceSam:赞成//@AliceSam:我觉得当今社会成长的孩子从小学习就够累了，不需要特意去学习炒股啦。但是可以了解一些相关的知识，对学习也是有帮助的。
  1,352 评论
  点赞
  分享
  举报
暂无粉丝

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4154062505860970","uuid":"4154062505860970","gmtCreate":1690959391921,"gmtModify":1735891657472,"name":"Lavon","pinyin":"lavon","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/51736c00b7c23c8dc3eb7d446ff13f2a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.02","exceedPercentage":"80.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.18","exceedPercentage":"60.80%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":424883212206984,"gmtCreate":1744763916728,"gmtModify":1744767044468,"author":{"id":"4154062505860970","authorId":"4154062505860970","name":"Lavon","avatar":"https://static.tigerbbs.com/51736c00b7c23c8dc3eb7d446ff13f2a","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4154062505860970","authorIdStr":"4154062505860970"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/424883212206984","repostId":"2527285744","repostType":2,"repost":{"id":"2527285744","kind":"news","pubTimestamp":1744700897,"share":"https://www.laohu8.com/m/news/2527285744?lang=&edition=full","pubTime":"2025-04-15 15:08","market":"hk","language":"zh","title":"映恩生物正式挂牌港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2527285744","media":"金融界","summary":"观点网讯：4月15日，映恩生物Duality Biotherapeutics, Inc.在香港联合交易所主板成功挂牌上市。映恩生物此次招股公开发售部分获115.14倍认购，国际发售部分获13.52倍认购。映恩生物此次IPO引入15名基石投资者，合共认购534.18万股发售股份，包括BioNTech、LAV Star等。截至最后实际可行日期，映恩生物在17个国家的230多个临床试验中心拥有七项全球多区域临床试验，已有2,000多名患者入组。","content":"<html><body><article><p><strong>观点网讯：</strong>4月15日，<a href=\"https://laohu8.com/S/09606\">映恩生物</a>Duality Biotherapeutics, Inc.（简称“映恩生物”）在香港联合交易所主板成功挂牌上市。</p><p>此次IPO全球发售1733.23万股H股，占发行完成后总股份的20.29%，每股下限定价94.60港元，募集资金总额约16.40亿港元，所得款净额约15.13亿港元。映恩生物此次招股公开发售部分获115.14倍认购，国际发售部分获13.52倍认购。</p><p>映恩生物此次IPO引入15名基石投资者，合共认购534.18万股（6500万美元，约5.05亿港元）发售股份，包括BioNTech、LAV Star等。基石投资者认购股份占全球发售股份数量的30.82%，占发售完成后总股份的6.25%。公司上市后的股东架构中，LAV USD持股19.51%，林向红博士最终控制的King Star Med持股7.71%，创办人控股公司持股7.61%，上海楹伽持股7.48%，<a href=\"https://laohu8.com/S/02269\">药明生物</a>（02269.HK）持股4.88%，陈飞最终控制的Orchids持股4.40%，<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>（01177.HK）通过Golden Sword持股3.90%，赵宁博士的遗产最终拥有的APHN，持股1.76%，Green Pine持股2.20%，华盖美元持股0.68%，华盖资本通过深圳华盖、苏州华盖、天津华盖分别持股0.73%、2.01%、0.98%，元禾控股通过中新创投持股2.93%，蔡茵茵通过七晟医药持股1.96%，<a href=\"https://laohu8.com/S/002029\">七匹狼</a>集团控制的晟联持股1.76%，<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>中金基金一、阿斯利康中金基金二分别持股1.96%，杭州泰鲲持股1.76%，<a href=\"https://laohu8.com/S/600535\">天士力</a>国际资本持股1.18%，周雅珍女士通过海博持股1.41%，汉康资本通过Hankang Biotech、Splendid Biotech分别持股0.94%、0.47%，其他公众股东持股19.83%。</p><p>映恩生物成立于2019年，作为抗体偶联药物（ADC）领域的全球领跑者，致力于为癌症和自身免疫性疾病等患者研发新一代ADC创新药物。公司设计的ADC候选药物可与全球领先ADC公司的产品匹敌或进行差异化竞争。公司有五项处于临床阶段的<span>资产</span>已获得美国食品药品管理局（FDA）及中国药监局的研究用新药（IND）批准。截至最后实际可行日期，映恩生物在17个国家的230多个临床试验中心拥有七项全球多区域临床试验（MRCT），已有2,000多名患者入组。公司的创新ADC资产已吸引领先的生物制药公司，并已建立数个全球合作伙伴关系，包括与BioNTech、<a href=\"https://laohu8.com/S/ONC\">百济神州</a>、Adcendo、GSK、Avenzo的合作，交易总价值逾60亿美元。</p><p>免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。</p><p>本文源自：观点网</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>映恩生物正式挂牌港交所</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n映恩生物正式挂牌港交所\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-15 15:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041515122497384778&s=b><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>观点网讯：4月15日，映恩生物Duality Biotherapeutics, Inc.（简称“映恩生物”）在香港联合交易所主板成功挂牌上市。此次IPO全球发售1733.23万股H股，占发行完成后总股份的20.29%，每股下限定价94.60港元，募集资金总额约16.40亿港元，所得款净额约15.13亿港元。映恩生物此次招股公开发售部分获115.14倍认购，国际发售部分获13.52倍认购。映恩生物...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041515122497384778&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09606":"映恩生物-B"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041515122497384778&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2527285744","content_text":"观点网讯：4月15日，映恩生物Duality Biotherapeutics, Inc.（简称“映恩生物”）在香港联合交易所主板成功挂牌上市。此次IPO全球发售1733.23万股H股，占发行完成后总股份的20.29%，每股下限定价94.60港元，募集资金总额约16.40亿港元，所得款净额约15.13亿港元。映恩生物此次招股公开发售部分获115.14倍认购，国际发售部分获13.52倍认购。映恩生物此次IPO引入15名基石投资者，合共认购534.18万股（6500万美元，约5.05亿港元）发售股份，包括BioNTech、LAV Star等。基石投资者认购股份占全球发售股份数量的30.82%，占发售完成后总股份的6.25%。公司上市后的股东架构中，LAV USD持股19.51%，林向红博士最终控制的King Star Med持股7.71%，创办人控股公司持股7.61%，上海楹伽持股7.48%，药明生物（02269.HK）持股4.88%，陈飞最终控制的Orchids持股4.40%，中国生物制药（01177.HK）通过Golden Sword持股3.90%，赵宁博士的遗产最终拥有的APHN，持股1.76%，Green Pine持股2.20%，华盖美元持股0.68%，华盖资本通过深圳华盖、苏州华盖、天津华盖分别持股0.73%、2.01%、0.98%，元禾控股通过中新创投持股2.93%，蔡茵茵通过七晟医药持股1.96%，七匹狼集团控制的晟联持股1.76%，阿斯利康中金基金一、阿斯利康中金基金二分别持股1.96%，杭州泰鲲持股1.76%，天士力国际资本持股1.18%，周雅珍女士通过海博持股1.41%，汉康资本通过Hankang Biotech、Splendid Biotech分别持股0.94%、0.47%，其他公众股东持股19.83%。映恩生物成立于2019年，作为抗体偶联药物（ADC）领域的全球领跑者，致力于为癌症和自身免疫性疾病等患者研发新一代ADC创新药物。公司设计的ADC候选药物可与全球领先ADC公司的产品匹敌或进行差异化竞争。公司有五项处于临床阶段的资产已获得美国食品药品管理局（FDA）及中国药监局的研究用新药（IND）批准。截至最后实际可行日期，映恩生物在17个国家的230多个临床试验中心拥有七项全球多区域临床试验（MRCT），已有2,000多名患者入组。公司的创新ADC资产已吸引领先的生物制药公司，并已建立数个全球合作伙伴关系，包括与BioNTech、百济神州、Adcendo、GSK、Avenzo的合作，交易总价值逾60亿美元。免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。本文源自：观点网","news_type":1,"symbols_score_info":{"09606":1}},"isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":356399005941784,"gmtCreate":1728020941441,"gmtModify":1728021626249,"author":{"id":"4154062505860970","authorId":"4154062505860970","name":"Lavon","avatar":"https://static.tigerbbs.com/51736c00b7c23c8dc3eb7d446ff13f2a","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4154062505860970","authorIdStr":"4154062505860970"},"themes":[],"htmlText":"Replying to <a href=\"https://laohu8.com/U/4087422624240810\">@AliceSam</a>:赞成//<a href=\"https://laohu8.com/U/4087422624240810\">@AliceSam</a>:我觉得当今社会成长的孩子从小学习就够累了，不需要特意去学习炒股啦。但是可以了解一些相关的知识，对学习也是有帮助的。","listText":"Replying to <a href=\"https://laohu8.com/U/4087422624240810\">@AliceSam</a>:赞成//<a href=\"https://laohu8.com/U/4087422624240810\">@AliceSam</a>:我觉得当今社会成长的孩子从小学习就够累了，不需要特意去学习炒股啦。但是可以了解一些相关的知识，对学习也是有帮助的。","text":"Replying to @AliceSam:赞成//@AliceSam:我觉得当今社会成长的孩子从小学习就够累了，不需要特意去学习炒股啦。但是可以了解一些相关的知识，对学习也是有帮助的。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/356399005941784","isVote":1,"tweetType":1,"viewCount":1352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"followers","isTTM":false}